Maine recalls
3583 federal recalls on file affecting Maine - 204 Maine-specific plus 3379 nationwide. Sourced from CPSC, FDA, USDA, and NHTSA.
- 2026-02-11FDA-DeviceBoston ScientificClass INationwideContact your doctor about AXIOS Stent
Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site.
- 2026-02-11FDA-DeviceBoston ScientificClass INationwideCheck HOT AXIOS Stent lot numbers immediately
Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site.
- 2026-02-11FDA-DeviceBoston ScientificClass INationwideContact your doctor about Boston Scientific AXIOS Stent
Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site.
- 2026-02-11FDA-DeviceBoston ScientificClass INationwideContact your doctor about AXIOS Stent recall
Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site.
- 2026-02-11FDA-DeviceBoston ScientificClass INationwideStop using Boston Scientific AXIOS Stent
Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site.
- 2026-02-11FDA-FoodB.C. Williams Bakery ServiceClass INationwideStop using B.C. Williams Swiss Chocolate Cake Mix
Undeclared Milk Allergen
- 2026-02-11FDA-FoodB.C. Williams Bakery ServiceClass INationwideStop using B.C. Williams Bakery Bread and Roll Mix
Undeclared Milk Allergen
- 2026-02-11FDA-FoodB.C. Williams Bakery ServiceClass INationwideStop using B.C. Williams Spice Cake Mix
Undeclared Milk Allergen
- 2026-02-11FDA-FoodImu-Tek Animal HealthClass IIStop using Imu-Tek Immuno-5 Colostrum Powder
Undeclared milk allergen
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam strawberry sea moss gel
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam sea moss gel
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam mango sea moss gel
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodOptiwizeClass IIINationwideStop using OptiWize Collagen Plus
The firm initiated a voluntary recall after NSF testing showed that labeled ingredient quantities did not align with analytical test results, manganese level was below label quantity.
- 2026-02-11FDA-FoodFazt & LoudClass IIINationwideStop drinking Fazt & Loud Lost and Found Energy
Recall is due to a misprint on the label that incorrectly identifies the total caffeine content on the can. The item contains 300mg of caffeine, instead of 150mg as provided on the can.
- 2026-02-11FDA-DrugSun PharmaceuticalClass IINationwideStop using Sun Pharmaceutical Diclofenac Sodium Gel
Failed Viscosity Specifications: Out of Specification (OOS) [slightly lower than the limit] result in viscosity for Diclofenac Sodium Gel, 3%.
- 2026-02-11FDA-DrugGranulesClass IINationwideStop using Granules trazodone 50 mg
Presence of Foreign Tablets/Capsules
- 2026-02-11FDA-DrugGreen LumberClass INationwideStop using Green Lumber Natural Fuel For Men
Marketed without an Approved NDA/ANDA: FDA analysis found this product to contain tadalafil
- 2026-02-11FDA-DrugUnichem PharmaceuticalsClass IINationwideStop using Unichem bisoprolol/hydrochlorothiazide tablets
cGMP Deviations: recall due to not meeting the N-Nitroso Bisoprolol impurity specification limits.
- 2026-02-09CPSCAirovaNationwideStop using Aroeve air purifiers immediately
The air purifiers can overheat and ignite, posing fire and burn hazards to consumers.
Get notified about new Maine recalls
Free weekly digest. Add Maine to your profile to filter alerts to your state.
Get the Sunday Brief